Previous 10 | Next 10 |
BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District Court, District of New Jersey, regarding Agreement of Settlement. UNITED STA...
– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14 th at 3:30 PM EDT – BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), ...
A late-stage influenza asset development is halted. The Janssen Pharmaceutical announced a strategic decision to discontinue the development of pimodivir, a Phase 3 clinical asset. The study results showed that pimodivir in combination with the standard of care (SOC) was very unlikely to demonst...
BOTHELL, WA, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced tod...
Gainers: VBI Vaccines (NASDAQ: VBIV ) +35% . More news on: VBI Vaccines Inc., Rekor Systems, Inc., BMC Stock Holdings, Inc., Stocks on the move, , Read more ...
Cocrystal Pharma (NASDAQ: COCP ) -25% after raising "bought deal" offering to $15M. More news on: Cocrystal Pharma, Inc., SunPower Corporation, Quidel Corporation, Stocks on the move, , Read more ...
Due to increased demand, book runner H.C. Wainwright & Co., has agreed to increase the size of the previous public offering Cocrystal Pharma's (NASDAQ: COCP ) shares of common stock and purchase ~14.3M shares (from 9.52M) at $1.05/share, for expected gross proceeds of ~$15M...
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced tod...
Cocrystal Pharma (NASDAQ: COCP ) -16.2% AH , entered into an underwriting agreement with H.C. Wainwright wherein the underwriter has agreed to purchase 9.52M shares at $1.05/share. More news on: Cocrystal Pharma, Inc., Healthcare stocks news, , Stocks on the move, Read more ....
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced tod...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...